- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries.
CARE Ratings Limited has reaffirmed Vimta Labs' bank facilities at CARE A; Stable / CARE A1, maintaining a Stable outlook. This reflects the company's robust FY26 financial performance, with healthy PBILDT margins (35.26%) and PAT margins (18.86%). Strong debt protection, very low gearing (0.01x), comfortable liquidity (₹69 Cr cash), established...
Significant increase in volume has been observed in Vimta Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Vimta Labs Limited has...
Vimta Labs has scheduled one-on-one meetings with investment analysts Mr. Lukas Davies (Oppenheimer Generations Asia) on 04 September 2026 and Mr. Karan Doshi (Abakkus Asset Management) on 09 September 2026. The purpose of these meetings is to understand the company's business operations.
Vimta Labs Limited has scheduled one-on-one meetings with institutional investors. These include a physical meeting with Mr. Lukas Davies from Oppenheimer Generations Asia and a virtual meeting with Mr. Karan Doshi from Abakkus Asset Management. The discussions aim to help the investors understand the company's business operations.